Should I buy, hold, or sell SPRB stock right now?

Spruce Biosciences Inc. (SPRB) currently earns a Roarable Rating of E (Strong Sell — SELL) with 34/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is SPRB's 12-month price target and RQD AI Jury consensus?

SPRB's 12-month base price target is $39.74 (range $31 to $135.45), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / SPRB

KZIA (47) OGI (45) CATX (33) NBP (34) ⌘ Pro Terminal →

Spruce Biosciences Inc. (SPRB) — RQD Stock Rating Cockpit

$44.55 -3.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $44.15

Spruce Biosciences Inc. (SPRB) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $133.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SPRB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SPRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Spruce Biosciences Inc. (NASDAQ: SPRB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $44.55 (-3.97% 1D, market cap $133.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SPRB ranks #633 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SPRB compare to KZIA and OGI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KZIA (Kazia Therapeutics Limited) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $132.2M) and OGI (Organigram Global Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $131.6M). Among the 5-stock peer group, SPRB leads on earnings multiple (N/A) while SPRB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SPRB?

▼

Per SPRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001683553), Spruce Biosciences Inc. generated $102.2M in revenue (+1981.8% YoY), -$39.0M in net income, and -$33.3M in free cash flow against $53.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $44.15 (-0.90%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SPRB)Realized 20D OHLCV Swing Band: ±12.2%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY SPRB SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 52.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$40.35+2.2% Next Q

Q2 (-2Q)

Grade E$41.23+10.7% Next Q

Q3 (-1Q)

Grade E$45.65-2.4% Next Q

Current

Grade E$44.55-8.7% Hist 90D α

Trajectory: E (26) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SPRB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SPRB currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($49.65) and Max Pain ($46.78) forces dealer call-delta covering toward $135.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SPRB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SPRB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

52.130 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE7% OF RANGE

L: $38$44.55H: $129

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on SPRB

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 42.0% gross margin and -24.77% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 0.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (33)

10/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like SPRB

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SPRB)

✓Walkthrough of SPRB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SPRB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -24.96%📐 HORIZONTAL RANGE

2026-11-03O $46.82H $46.82L $44.55C $44.55VOL 66.0K

RES: $67.14SUP: $37.48SMA50: $49.65SMA200: $55.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SPRB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SPRB Butterfly Map → + Track SPRB →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +1981.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SPRB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SPRB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SPRB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SPRB)

Health Care Rank #633 of 1015 ⚔️ KZIA vs SPRB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SPRB vs. KZIA, OGI, CATX, NBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Spruce Biosciences Inc. (SPRB) ranks #633 by composite RQD confidence (34/100, grade E) and #619 by equity capitalization ($133.3M). Within this direct 5-issuer industry benchmark cohort, SPRB leads on earnings valuation at N/A trailing P/E, while SPRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KZIA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SPRB at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SPRB ACTIVE Spruce Biosciences Inc.	E	34/100	—	—	-35.0%	-3.97%	$133.3M	Benchmark Subject
KZIA Kazia Therapeutics Limited	D	47/100	—	—	—	-5.65%	$132.2M	/kzia-vs-sprb →
OGI Organigram Global Inc.	D	45/100	—	—	—	+3.43%	$131.6M	/ogi-vs-sprb →
CATX Perspective Therapeutics Inc.	E	33/100	—	—	-35.0%	-9.56%	$131.3M	/catx-vs-sprb →
NBP NovaBridge Biosciences	E	34/100	—	—	-35.0%	-10.46%	$137.9M	/nbp-vs-sprb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001683553 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Spruce Biosciences Inc. (SPRB) reported GAAP revenue of $102.2M (+1981.8% vs. FY2024 revenue of $4.9M , and +913.3% cumulative change since FY2023) , GAAP net income of -$39.0M, operating cash flow of -$33.3M, and free cash flow of -$33.3M (+40.4% YoY). On the balance sheet, SPRB closed FY2025 with $53.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$102.2M	-$39.0M	-$33.3M	-$33.3M	$53.0M	$0
FY2024 (FY)	2024-12-31	$4.9M	-$53.0M	-$56.0M	-$56.0M	$45.2M	$124.0K
FY2023 (FY)	2023-12-31	$10.1M	-$47.9M	-$33.3M	-$33.3M	—	—

3. SPRB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SPRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SPRB compare to KZIA and OGI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SPRB?

Where is SPRB trading relative to its 50-day, 200-day, and 52-week technical levels?

SPRB last traded at $44.55 (-3.97% on volume of 90,551 shares), positioning the stock -10.27% below its 50-day simple moving average ($49.65) and -19.73% below its 200-day simple moving average ($55.50). Across its 52-week range of $38.06 to $129.00, SPRB sits at the 7.1% percentile with a 14-day RSI of 52.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.2% ($39.11 to $49.99).

Direct Sub-Reports: SPRB RQD Cockpit SPRB 12M Forecast SPRB Earnings & Move SPRB Dividends & DRIP SPRB Insiders & 13F SPRB Whale Options SPRB Profit Sankey SPRB News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

SPRB — Spruce Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Spruce Biosciences Inc. (SPRB) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $44.55 (-3.97% 1D, market capitalization $133.3M).

Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -24.77%.
Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of 0.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Spruce Biosciences Inc. (SPRB) is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the recent news catalysts, the company is associated with MPS IIIB natural history data, indicating a focus on rare disease research.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Spruce Biosciences Inc. (SPRB) reported $102.2M in annual revenue (up from $4.9M in FY2024, +1981.8% YoY) and -$39.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($10.1M revenue, -$47.9M net income) through FY2025, SPRB scaled operating cash flow to -$33.3M and free cash flow to -$33.3M, backed by $53.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -24.77% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $38.06 – $129.00 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or proprietary signal links are recorded. Upstream/downstream dependency mapping: — Sector correlation data: — Second-order bottlenecks: — Investors should note that the absence of mapped links means this analysis cannot identify ripple effects from peers or suppliers.

Key Question #1: Can SPRB sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $102.2M and free cash flow of -$33.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SPRB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SPRB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Spruce Biosciences Inc. (SPRB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SPRB Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference

Yahoo Finance report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

B.Riley reiterates Buy on Spruce Biosciences stock, $160 target

Investing.com report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting

Yahoo Finance report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Spruce Biosciences (SPRB) Rallies 3.87% to $41.97 as Shares Press Toward Upper Range - Safe Entry Stocks

https://www.siam.in/ report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Spruce Biosciences, Inc. (SPRB) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

Spruce Biosciences Q2 2026 Earnings: Wider-Than-Expected Loss Pressures Shares - Upward Estimate Revision

https://www.dars.gov.et/ report covering Spruce Biosciences Inc. (SPRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 17h ago

Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

SOUTH SAN FRANCISCO, Calif., November 02, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with si

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SPRB Bull vs. Bear Conversation Board — What's Your Call at $44.55?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SPRB 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $53.81 (+16.0%)

📌 Pinned Debate

Net cash of $48.9M against $0.0M debt in FY 2025 gives the company a balance sheet with no reported debt burden.

Picked up a starter position in SPRB in my $100K Virtual Cash book at $46.39. Net cash of $48.9M against $0.0M debt in FY 2025 gives the company a balance sheet with no reported debt burden.. Trading inside a $38.06–$129.00 52-week range with -24.77% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

EarningsSniper 🐂 BULL

@MultipleCompression Shorting a 5/20 institutional whale-flow stock at $46.39 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $35.26 (-24.0%)

Spot @ $46.39

Revenue fell from $10.1M to $0.0M over two years while FCF remained negative at -$33.3M, with an Altman Z-Score of 0.2.

Here is the bear case nobody on the bull side wants to address on SPRB: Revenue fell from $10.1M to $0.0M over two years while FCF remained negative at -$33.3M, with an Altman Z-Score of 0.2.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.